指南与共识认知障碍与痴呆

阿尔茨海默病作为临床-生物学构建——国际工作组推荐

Alzheimer Disease as a Clinical-Biological Construct-An International Working Group Recommendation.
指南 / 共识 · JAMA Neurol · 2024-01-01

国际工作组(IWG)基于PubMed检索2020年7月1日至2024年3月1日文献,审视修订版阿尔茨海默病协会(AA)标准,提出将阿尔茨海默病作为临床-生物学构建用于临床,并更新2021年IWG诊断标准以细化高危和症状前状态。工作组认为仅淀粉样蛋白阳性且认知正常者不应被标记为阿尔茨海默病,而应视为阿尔茨海默病风险人群。

要点

  • 仅核心1生物标志物阳性而认知正常者,多数不会在近期出现症状。
  • 仅淀粉样蛋白阳性及多数生物标志物阳性认知正常者不应被标记为阿尔茨海默病。
  • 上述人群应被视为阿尔茨海默病风险人群,而非阿尔茨海默病患者。

核心结论

  • 将无临床-生物学构建者诊断为阿尔茨海默病缺乏依据,且在不知晓症状何时或是否出现时可能令人担忧。
  • 仅淀粉样蛋白阳性及更广泛地多数生物标志物阳性认知正常个体不应被标记为阿尔茨海默病,而应视为阿尔茨海默病风险人群。
  • 症状前阿尔茨海默病的扩展被视为对具有特定生物标志物模式、提示近期将出现症状者的更好诊断构建。

研究设计与样本

  • 国际工作组(IWG)推荐文件,检索PubMed 2020年7月1日至2024年3月1日文献,并检索相关文章参考文献。

主要发现

  • 新AA诊断标准中,阿尔茨海默病可在临床上定义为包括具有核心1阿尔茨海默病生物标志物的认知正常者。
  • 近期文献显示,多数生物标志物阳性认知正常个体不会在近期时间线内出现症状。
  • 在临床环境中,向仅有核心1阿尔茨海默病生物标志物的认知正常者披露阿尔茨海默病诊断,是纯生物学定义最具问题的推论。

关键数值与推荐

  • 推荐仅淀粉样蛋白阳性者及更广泛地多数生物标志物阳性认知正常个体不应被标记为阿尔茨海默病,而应视为阿尔茨海默病风险人群。
  • 症状前阿尔茨海默病的扩展被视为对具有特定生物标志物模式、提示近期将出现症状者的更好诊断构建。

临床怎么用

  • 临床中不应将仅有核心1阿尔茨海默病生物标志物的认知正常者标记为阿尔茨海默病,应视为阿尔茨海默病风险人群。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Since 2018, a movement has emerged to define Alzheimer disease (AD) as a purely biological entity based on biomarker findings. The recent revision of the Alzheimer's Association (AA) criteria for AD furthers this direction. However, concerns about a purely biological definition of AD being applied clinically, the understanding of AD by society at large, and the translation of blood-based biomarkers into clinical practice prompt these International Working Group (IWG) updated recommendations. OBJECTIVE: To consider the revised AA criteria and to offer an alternative definitional view of AD as a clinical-biological construct for clinical use. The recommendations of the 2021 IWG diagnostic criteria are updated for further elaborating at-risk and presymptomatic states. EVIDENCE REVIEW: PubMed was searched for articles published between July 1, 2020, and March 1, 2024, using the terms "biomarker" OR "amyloid" OR "tau" OR "neurodegeneration" OR "preclinical" OR "CSF" OR "PET" OR "plasma" AND "Alzheimer's disease." The references of relevant articles were also searched. FINDINGS: In the new AA diagnostic criteria, AD can be defined clinically as encompassing cognitively normal people having a core 1 AD biomarker. However, recent literature shows that the majority of biomarker-positive cognitively normal individuals will not become symptomatic along a proximate timeline. In the clinical setting, disclosing a diagnosis of AD to cognitively normal people with only core 1 AD biomarkers represents the most problematic implication of a purely biological definition of the disease. CONCLUSIONS AND RELEVANCE: The ultimate aim of the field was to foster effective AD treatments, including preventing symptoms and dementia. The approach of diagnosing AD without a clinical and biological construct would be unwarranted and potentially concerning without a clear knowledge of when or whether symptoms will ever develop. It is recommended that those who are amyloid-positive only and, more generally, most biomarker-positive cognitively normal individuals, should not be labeled as having AD. Rather, they should be considered as being at risk for AD. The expansion of presymptomatic AD is viewed as a better diagnostic construct for those with a specific pattern of biomarkers, indicating that they are proximate to the expression of symptoms in the near future.

来源:JAMA Neurol,查看原文。版权归原作者所有。

引用

  1. Dubois B, Villain N, Schneider L, et al. Alzheimer Disease as a Clinical-Biological Construct-An International Working Group Recommendation. JAMA Neurol. 2024. PMID: 39483064. doi:10.1001/jamaneurol.2024.3770

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。